Short description
Research and development company in biotechnology aiming for a functional cure to diabetes through patented Neo-Islets™ technology
Description
SymbioCellTech is a biotechnology company that has developed a patented, proprietary therapy to cure insulin-dependent Type I diabetes Mellitus (T1DM), which is commonly referred to as Type 1 or juvenile onset diabetes. In summary it is been shown that through an intra-abdominal administration of SymbioCellTech Neo-Islets™ (NIs; a cellular therapeutic) has been shown in multiple animal models of Type 1 Diabetes to result in long-term glucose control with reduced or no need for insulin injections, and with no need for toxic antirejection drugs. The durable blood glucose control along with the absence of an immune response demonstrate that NIs provide protection from autoimmune attacks that ordinarily destroy insulin-producing cells in Type 1 Diabetes, and provide an endogenous and physiologic source of insulin.
Last funding
Uh Ohhhh
Sign in for full access
Total funding
$$121212
Sign in for full access
Location
Salt Lake City, Utah, United States, North America
Founded on
April 25, 2006
Non-profit?
No
Acquired?
No
Employees count
1-10
Revenue range
$7890 - 12340
Sign in for full access
Founders
Christof Westenfelder